Wedbush raised the firm’s price target on CytomX Therapeutics (CTMX) to $11 from $6 and keeps an Outperform rating on the shares. The firm notes the company announced updated expansion data for Varseta-M in patients with advanced colorectal cancer, with Q4 financials and other corporate updates.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CTMX:
- CytomX Therapeutics Confronts Rising AI Regulatory Risks and Cost Pressures
- CytomX Therapeutics announces $250M common stock offering
- CytomX Therapeutics files automatic mixed securities shelf
- Varseta-M’s Differentiated Efficacy in Late-Line Colorectal Cancer Drives Higher Approval Odds and Upside to Target Price
- CytomX Therapeutics price target raised to $17 from $10 at H.C. Wainwright